Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01642342 · ClinicalTrials.gov registry record · Phase 1
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
NCT01642342 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 102 participants.
The verdict
NCT01642342, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
Study Summary
This study is about an experimental drug called sEphB4-HSA (recombinant albumin fusion protein sEphB4-HSA). This research study will be the first time sEphB4-HSA is given to people. sEphB4-HSA prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. sEphB4-HSA has shrunk colon, lung, breast, glioma, melanoma, prostate and Kaposi's sarcoma tumors in mice
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- BIOLOGICAL recombinant albumin fusion protein sEphB4-HSA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2012-09-06 |
| Est. Completion | 2019-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01642342
The ClinicalTrials.gov registry entry for NCT01642342 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01642342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01642342 about?
NCT01642342 is a clinical study titled "Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors". This study is about an experimental drug called sEphB4-HSA (recombinant albumin fusion protein sEphB4-HSA). This research study will be the first time sEphB4-HSA is given to people. sEphB4-HSA prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels...
What is the current status of trial NCT01642342?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2012-09-06. Estimated completion is 2019-05-29.
What interventions are being tested in trial NCT01642342?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), recombinant albumin fusion protein sEphB4-HSA (BIOLOGICAL).
Who is sponsoring clinical trial NCT01642342?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.